Synaffix to Present Key ADC Technology Data on SYNtecan E Linker-Payload at World ADC Conference
Virtual poster presentation shows complete tumor regression and high tolerability of a SYNtecan E™ based ADC SYNtecan E™ linker-payload is a potent exatecan-based, DNA topoisomerase 1 inhibitor developed by Synaffix Data underscores ability of Synaffix’s technologies...
Third ADC with Synaffix’s Technology Enters Clinical Development
AMSTERDAM, NETHERLANDS, September 29, 2021 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that its...
BGV Expands Team with the Appointment of a Partner and Venture Partner
Naarden, The Netherlands, 14 September 2021 – BioGeneration Ventures (“BGV”), a leading early-stage VC in European biopharma, today announces the appointment of Keno Gutierrez as Partner, and Wouter Verhoeven as Venture Partner. Collectively these two appointments...
Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology
First-in-human study evaluating CIT-013, a humanized monoclonal antibody targeting Neutrophil Extracellular Traps (NETs)CIT-013 binds to citrullinated Histones H2A and H4CIT-013 inhibits NET formation, promotes tissue NET clearance, and hence blocks the...
Kyowa Kirin Taps Synaffix ADC Technology to Expand Its Pipeline
Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and select toxSYN™ linker-payloads Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized...
Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies
Amsterdam, The Netherlands , July 22, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announced the signature of a...
VarmX to Present New Data on Lead Compound, VMX-C001,
at the ISTH 2021 Virtual Congress
Leiden, The Netherlands, 19 July 2021 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that new preclinical data on VMX-C001 has been selected to be presented during an oral...
Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer
Leiden, The Netherlands, June 30, 2021 – Azafaros B.V. today announced that Stefano Portolano, M.D., has joined Azafaros as Chief Executive Officer (CEO) and has concurrently been appointed to the Board of Directors of the company. Dr. Portolano is an experienced...
Synaffix Licenses its Award-Winning ADC Technology in Deal Adding a New ADC to Innovent’s Pipeline
AMSTERDAM, NETHERLANDS – June 29, 2021 – Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today...
VectorY raises €31 million in seed financing to develop next-generation gene therapies aimed at muscular and CNS disorders
Amsterdam, The Netherlands, 15 June 2021 – VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces the...